Warren Wallo worked in R&D at Johnson & Johnson Consumer Companies, Inc. for 25 years before retiring in April 2013. Upon retirement, he established Wallo Research & Consulting LLC and throughout the past five years, he has provided consultation services to many leading companies, leveraging his unique background, contacts and experience across the pharmaceutical and consumer products industries.
During his tenure at J&J, he served as the Director of Scientific Engagement with a focus on clinical research for numerous scientifically based skincare brands. He also served as the Director of the Active Naturals® Research Institute™ for which he represented the skincare benefits of natural ingredients such as colloidal oatmeal and Total Soy™. Prior to that, he served as the Director of Scientific Affairs, where he demonstrated scientifically based skincare benefits through clinical testing, laboratory investigations and instrumental assessment. To further product development, he aided in the formation and substantiation of bold new claims for skincare products in the mass-market channel of trade. Additionally, he represented the science behind beauty products through interaction with the beauty press and in the professional realm, as well as communication with consumers.
He often functioned as the R&D spokesperson to the media, medical professionals and key customers to bring a strategic focus to the communication of science and innovation. He was also responsible for R&D/Technical presentations at key dermatology meetings and oversaw the distribution of educational and research grants to dermatology and University research groups for Skincare R&D. He has moderated dermatologist roundtables, including at the 2011 World Congress of Dermatology in Seoul, Korea on the topic of “Multicultural perspectives on the role of natural ingredients in dermatology” from which a scientific manuscript based on the proceedings was published. He has published a chapter entitled “Dermatoscopy in Cosmetic Applications” in the textbook Dermatoscopy in Clinical Practice, edited by Giuseppe Micali, MD and Francesco Lacarrubba, MD, Informa Healthcare; London, UK 2010. He has also been featured and quoted in several beauty publications including Elle, Good Housekeeping and Dermatology Times. He also published an article in an international dermatology journal on soy, co-authored with Dr. James Leyden.
Prior to joining Johnson & Johnson Consumer Companies, Inc., Wallo fostered his scientific knowledge in pharmaceuticals. He first began as a scientist in Rx Quality Control at CIBA-Geigy Pharmaceuticals in Summit, New Jersey, which later became the NOVARTIS Corporation. In his second position at Knoll Pharmaceuticals of BASF in Whippany, New Jersey, Wallo worked as an Analytical Research Senior Scientist and Manager on developing new test methods, validation, stabilization and preparation. His role included the preparation of the Manufacturing/Controls section of NDAs for the launch of new prescription drugs, including verapamil HCl, the first calcium channel blocker in the United States.
He received his B.S. degree in Chemistry and M.S. in Analytical Chemistry at Seton Hall University in South Orange, New Jersey. Wallo has been an adjunct member of the American Academy of Dermatology and the lead author on numerous AAD scientific posters, specializing in the area of anti-aging, acne, eczema and dry skin. He has also served as a member of CEW and the Society of Cosmetic Chemists and remains a career-long member of the American Chemical Society.